NCT04029350 (ALTN-03) is a Phase 2 clinical trial of Anlotinib Combined With Osimertinib in Non Small Cell Lung Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT04029350?

NCT04029350 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT04029350?

Interventions in NCT04029350: Anlotinib Combined With Osimertinib.

What condition does NCT04029350 study?

NCT04029350 studies Non Small Cell Lung Cancer.

Is NCT04029350 still recruiting?

NCT04029350 is currently status unknown. Last updated 21 August 2019.

Last reviewed 2019-08-21 · How we verify

NCT04029350: ALTN-03

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M

Status unknown Phase 2 Last updated 21 August 2019

What this trial tests

Phase 2 trial testing Anlotinib Combined With Osimertinib in Non Small Cell Lung Cancer in 53 participants. Status unknown.

Timeline

31 July 2019

Primary endpoint
31 January 2020

30 November 2021

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	53
Start date	31 July 2019
Primary completion	31 January 2020
Estimated completion	30 November 2021
Sites	4 locations across China

Drugs / interventions tested

Anlotinib Combined With Osimertinib — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 75, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the efficacy and safety of Anlotinib combined with Icotinib as the second-line treatment in stage IIIb-IV NSCLC patients with sensitive EGFR and T790M mutations.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data.
Lee CS, Milone M, Seetharamu N. · · 2021 · cited 24× · PMID 34471361 · DOI 10.2147/ott.s227032
Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors.
Sun SY. · · 2023 · cited 12× · PMID 37609474 · DOI 10.1016/j.pccm.2022.10.001
Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.
Wang X, Li Z, Wang L, Liang Y, et al · · 2025 · cited 6× · PMID 40234867 · DOI 10.1186/s12916-025-04044-8
Efficacy and safety of anlotinib plus EGFR-TKI for advanced non-small cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
Li D, Du Y, Che Y, Cheng C, et al · · 2025 · PMID 41261607 · DOI 10.1097/md.0000000000045654

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04029350 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 21 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04029350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing